Bos Sci's Ion, Taxus Libert nab FDA approval for acute MI patients
Boston Scientific's Ion paclitaxel-eluting platinum chromium coronary stent system and Taxus Liberté paclitaxel-eluting coronary stent system have received FDA approval for use in patients experiencing acute MI (AMI).
Currently, they are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with AMI. The new indication is a result of FDA review of data from the Paclitaxel (Taxus) clinical program and HORIZONS-AMI trial.
The company said the Ion stent system incorporates a platinum chromium alloy designed specifically for coronary stenting and the acute performance of coronary stent implantation in the treatment of coronary artery disease.
Currently, they are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with AMI. The new indication is a result of FDA review of data from the Paclitaxel (Taxus) clinical program and HORIZONS-AMI trial.
The company said the Ion stent system incorporates a platinum chromium alloy designed specifically for coronary stenting and the acute performance of coronary stent implantation in the treatment of coronary artery disease.